Screener
Monopar Therapeutics MNPR Operating Income
Operating Income at other companies
Other financials
Where this comes from
Reported directly by Monopar Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.
The source filing: Monopar Therapeutics’s 10-Q, filed May 14, 2026.
- Filed
- May 14, 2026, 2:00 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001437749-26-016982
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Research and development | $3,487,247 | $1,643,375 |
| General and administrative | 1,738,006 | 1,578,442 |
| Total operating expenses | 5,225,253 | 3,221,817 |
| Income (loss) from operations | (5,225,253) | (3,221,817) |
| Interest income (loss) | 1,332,203 | 596,845 |
| Net income (loss) | (3,893,050) | (2,624,972) |
| Other comprehensive income (loss): | ||
| Foreign currency translation gain (loss), net | (190) | 1,239 |
Document
FAQ
- What is Monopar Therapeutics's operating income?
- Monopar Therapeutics (MNPR) reported operating income of -$5.23M in Q1 2026.
- How has Monopar Therapeutics's operating income changed year-over-year?
- Monopar Therapeutics's operating income decreased by 62.2% year-over-year, from -$3.22M to -$5.23M.
- What is the long-term trend for Monopar Therapeutics's operating income?
- Over 4 years (2021 to 2025), Monopar Therapeutics's operating income has grown at a 16.3% compound annual growth rate (CAGR), from -$9.13M to -$16.7M.
- What does operating income mean?
- Gross profit minus all operating expenses (SG&A, R&D, D&A). Measures the profit from core business operations before interest, taxes, and non-operating items.
Ask your AI about Monopar Therapeutics's operating income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude